Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics is a commercial-stage medical diagnostics technology company with a positive outlook due to its potential for Medicare coverage for its EsoGuard test, a high-value market opportunity for its EsoGuard and EsoCheck products, and its recent regulatory and commercial successes, such as its Laboratory Benefit Manager (LBM) contract with Concert and its positive coverage from Highmark BCBS. Additionally, the company has enough cash on hand to sustain operations for the next few years and is making progress in expanding its sales force and securing contracts with commercial health plans.

Bears say

Lucid Diagnostics is yet to generate significant revenue despite its Q2'26 revenue growth of 27% YoY. Its flagship product, EsoGuard, which has FDA breakthrough device designation and has been commercialized as an LDT, has potential to be a revolutionary solution for the large unmet need in preventing esophageal adenocarcinoma. However, there are concerns about the company's cash usage, competition, and lack of Medicare coverage, which, if not addressed, could hinder the company's growth potential.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.